Veliparib and Carboplatin May Be Effective Against Triple-negative Breast Cancer

Share this content:
Veliparib and carboplatin may together be an effective treatment for patients with clinical stage II or III breast cancer.
Veliparib and carboplatin may together be an effective treatment for patients with clinical stage II or III breast cancer.

Editor's Note: The first paragraph of a previous version of this article used the phrase "clinical stage II or II breast cancer." This has been changed to "clinical stage II or III."

Veliparib and carboplatin may together be an effective treatment for patients with clinical stage II or III breast cancer, according to an article published recently in the New England Journal of Medicine.1

The Investigation of Serial Studies to Predict Your Therapeutic Response through Imaging and Molecular Analysis 2 (I-SPY 2) is a multicenter, randomized, phase 2 trial in which investigators contrast experimental regimens against controls for the treatment of breast cancer, which is difficult to treat with targeted therapies, due to the heterogeneousness of the disease.

Seventy-two patients were assigned to receive veliparib, an oral therapy that preclinical models have shown to potentiate the antineoplastic effect of carboplatin, in conjunction with carboplatin. Forty-four patients were assigned to control therapy.

RELATED: Neratinib May Be Efficacious for Treatment of HER2-Positive Breast Cancer

Among patients with triple-negative breast cancer, the pathological complete response rate was 51% for the experimental regimen, in contrast with 26% for patients in the control group. Grade 3 to 4 adverse events were, however, far more common in the veliparib-carboplatin group, with 71% versus 0% of patients in the control group experiencing neutropenia, 21% versus 0% experiencing thrombocytopenia, and 28% versus 0% experiencing anemia.

The authors conclude that the experimental regimen has an 88% probability of success in a phase 3 trial.

Reference

  1. Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparib–carboplatin treatment in breast cancer. N Engl J Med. 7 Jul 2016. doi: 10.1056/NEJMoa1513749 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs